NEW YORK (GenomeWeb) – Agilent Technologies announced today that it has agreed to acquire ACEA Biosciences for $250 million in cash.

Privately held ACEA, which is based in San Diego, has most recently developed a line of xCELLigence impedance-based, label-free, real-time cell analysis instruments that are used in immuno-oncology, pre-clinical drug discovery and development, as well as in basic academic research. The company also sells a line of NovoCyte and NovoCyte Quanteon high-performance benchtop flow cytometry systems.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.